ANDA Submissions – Amendments and Requests for Final Approval to Tentatively Approved ANDAs

Dec 2025

On December 16, 2025, the USFDA released updated guidance regarding ANDA Submissions—Amendments and Requests for Final Approval to Tentatively Approved ANDAs. This guidance is a revision (Revision 2) of the agency’s current thinking on how generic drug applicants should manage amendments to their Abbreviated New Drug Applications (ANDAs).

Key Highlights of the December 2025 Update

This guidance aims to maximize the efficiency of the assessment cycle and reduce the number of cycles required for ANDA approval, facilitating faster access to generic medicines for patients.

• ANDA Approval Pathway: Unlike a New Drug Application (NDA), an ANDA applicant does not need to provide independent evidence of safety and effectiveness; instead, they rely on the FDA’s finding for a Reference Listed Drug (RLD).
• GDUFA III Commitments: The update aligns with performance goals and program enhancements under the Generic Drug User Fee Amendments of 2022 (GDUFA III), which covers fiscal years 2023 through 2027.
• Procedural Efficiency: It provides instructions for industry on how to submit amendments and request final approval for applications that have already received “tentative approval” (which occurs when an ANDA meets all requirements but cannot be fully approved due to patent or exclusivity protections).

Context on Postmarketing Adverse Event Reporting

While the specific document you linked (media/119718) was updated in December 2025 for ANDA submissions, the FDA also maintains critical guidance for Postmarketing Adverse Event Reporting During a Pandemic.

• Pandemic Reporting Strategy: In the event of a pandemic, the FDA allows firms to prioritize resources on reports related to products treating or preventing the pandemic pathogen.
• Enforcement Discretion: The FDA does not intend to object if certain non-priority adverse event reports are delayed due to high employee absenteeism during a pandemic, provided firms document the conditions and eventually submit all stored reports within six months of returning to a pre-pandemic state.
• Excluded Reports: This flexibility typically does not apply to reports for pandemic-related vaccines, products approved within the last three years, or serious 15-day “alert reports” for certain biologics.